Gwen Melincoff - Kamada Director

KMDA Stock  ILA 2,056  11.00  0.53%   

Director

Ms. Gwen A. Melincoff serves as Director of the Company. Ms. Melincoff is currently an advisor to Phase 1 Ventures, an accelerator startup program, and Verge Genomics, a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc., a UKbased specialist healthcare company. From 2004 to 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, from 2010 to 2013, she led the company Strategic Investment Group . Prior to joining Shire, Ms. Melincoff held managerial and business development positions at various pharmaceutical companies, including Adolor Corporation since 2017.
Age 67
Tenure 7 years
Phone(972) 8 9406472
Webwww.kamada.com
Melincoff has served as a board member/board observer at Tobira Therapeutics, DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc., and Enterome.

Kamada Management Efficiency

Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 17.41 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kamada has a current ratio of 6.72, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kamada until it has trouble settling it off, either with new capital or with free cash flow. So, Kamada's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kamada sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kamada to invest in growth at high rates of return. When we think about Kamada's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Saul LapidusDiscount Investment Corp
37
Adva SharvitAlony Hetz Properties
40
Moshe RosenthalB Communications
48
Ron MiloDelek Group
67
Carmit ElroyDelek Group
50
Dov KotlerBezeq Israeli Telecommunication
60
Ilan BiranBezeq Israeli Telecommunication
70
Moshe AmitDelek Group
79
Shimon DoronDelek Group
57
Itzhak ForerAlony Hetz Properties
82
Sharon AvidarB Communications
37
Or ElovitchBezeq Israeli Telecommunication
40
Zeev VurembrandBezeq Israeli Telecommunication
66
Joseph SingerDiscount Investment Corp
58
Shlomo ShuvAlony Hetz Properties
45
Niv AhituvDiscount Investment Corp
71
David GranotBezeq Israeli Telecommunication
71
Alejandro ElsztainDiscount Investment Corp
51
Arie ZeifDelek Group
70
Amos YadlinAlony Hetz Properties
65
Doron TurgemanBezeq Israeli Telecommunication
49
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 408 people. Kamada (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 355 people.

Management Performance

Kamada Leadership Team

Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pnina Strauss, Vice President - Inhalation programs & IP
Itzhak Krinsky, Director
Lilach Topilsky, Chairman of the Board
Ari Shamiss, Director
Barak Bashari, Vice President - Operations
Eran Schenker, Vice President - Medical Director
Tuvia Shoham, Independent Director
Eran Nir, Chief Officer
Hanni Neheman, VP Sales
Michal Stein, Vice President and Medical Director for Immunology
Ariella Raban, VP HR
Shani Dotan, Vice President of Human Resources
Liliana Bar, VP of RandD
Yael Brenner, Vice President - Quality
Abraham Havron, Independent Director
Asaf Frumerman, Director
Ruth Wolfson, Senior Vice President - Scientific Affairs
Shmuel Rubinstein, Director
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases
Jon Knight, VP Operations
Michael Berelowitz, Director
David Tsur, Co-Founder and Deputy Executive Chairman
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
Leon Recanati, Chairman of the Board
Gil Efron, CFO, Principal Accounting Officer and Deputy CEO
Jonathan Hahn, Director
Eran Schenkar, Vice President - Medical Director
Gwen Melincoff, Director
Chaime Orlev, Chief Financial Officer
Michal Ayalon, Vice President - Research & Development
Yifat Esq, Gen Legal
Amir London, Chief Executive Officer
Estery GilozRan, Independent Director
Reuven Behar, Director
Eitan Kyiet, Vice President - Business Development
Ziv Kop, Director

Kamada Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kamada in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kamada's short interest history, or implied volatility extrapolated from Kamada options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Kamada Stock analysis

When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.